Get the Stockscreener App
7.42
2.77%
0.20
After Hours:
7.45
0.03
+0.40%
Iteos Therapeutics Inc stock is traded at $7.42, with a volume of 2.15M.
It is up +2.77% in the last 24 hours and down -5.48% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$7.22
Open:
$7.17
24h Volume:
2.15M
Relative Volume:
3.64
Market Cap:
$271.08M
Revenue:
$127.70M
Net Income/Loss:
$-108.14M
P/E Ratio:
-9.0488
EPS:
-0.82
Net Cash Flow:
$-117.52M
1W Performance:
-3.39%
1M Performance:
-5.48%
6M Performance:
-49.66%
1Y Performance:
-28.38%
1-Day Range:
$7.09
$7.51
1-Week Range:
$7.09
$7.96
52-Week Range:
$7.09
$18.75
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
7.42 | 271.08M | 127.70M | -108.14M | -117.52M | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo - Yahoo Finance
iTeos Therapeutics (NASDAQ:ITOS) Price Target Cut to $19.00 by Analysts at Wells Fargo & Company - MarketBeat
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy - MSN
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report - BioCentury
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 - Seeking Alpha
Charles Schwab Investment Management Inc. Buys 8,397 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics’ (ITOS) Buy Rating Reiterated at HC Wainwright - Defense World
iTeos Therapeutics (NASDAQ:ITOS) Earns Buy Rating from HC Wainwright - MarketBeat
Iteos Therapeutics stock hits 52-week low at $7.52 - Investing.com India
Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data - BioSpace
Inupadenant shows promise in NSCLC Phase 2 trial results - Investing.com
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial - GlobeNewswire
ITeos Therapeutics, Inc. Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress - Marketscreener.com
Intech Investment Management LLC Invests $154,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
RA Capital Management L.P. Cuts Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
(ITOS) Technical Data - Stock Traders Daily
Quest Partners LLC Has $113,000 Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Vestal Point Capital LP Has $10.47 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat
Victory Capital Management Inc. Lowers Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Algert Global LLC - MarketBeat
iTeos annonce sa participation aux prochaines journées Investisseurs - GlobeNewswire Inc.
iTeos to Participate in Upcoming Investor Conferences - GlobeNewswire
iTeos Therapeutics to Present at Evercore and Piper Sandler Healthcare Conferences | ITOS Stock News - StockTitan
GSA Capital Partners LLP Purchases New Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Empowered Funds LLC Increases Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
(ITOS) On The My Stocks Page - Stock Traders Daily
BIOTECHNOLOGY VALUE FUND L P Increases Stake in ITeos Therapeuti - GuruFocus.com
Iteos Therapeutics stock hits 52-week low at $7.58 By Investing.com - Investing.com South Africa
Insider Buying: Matthew Gall Acquires 5,000 Shares of ITeos Ther - GuruFocus.com
Iteos Therapeutics stock hits 52-week low at $7.58 - Investing.com
iTeos Therapeutics CFO Matthew Gall acquires $38,635 in common stock - Investing.com India
iTeos Therapeutics CFO Matthew Gall acquires $38,635 in common stock By Investing.com - Investing.com UK
Equities Analysts Offer Predictions for ITOS FY2024 Earnings - Defense World
US Bancorp DE Has $123,000 Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - Simply Wall St
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for iTeos Therapeutics (NASDAQ:ITOS) - MarketBeat
EcoR1 Capital, LLC Reduces Stake in ITeos Therapeutics Inc - GuruFocus.com
FY2024 EPS Forecast for iTeos Therapeutics Lifted by Analyst - MarketBeat
Iteos Therapeutics stock hits 52-week low at $8.39 - Investing.com
Wedbush Reaffirms Outperform Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
iTeos Therapeutics Reports Q3 2024 Financial Results - TipRanks
Creative Planning Acquires 1,196 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
iTeos Reports Wider Q3 Loss, Maintains $684M Cash Runway Through 2027 | ITOS Stock News - StockTitan
Iteos Therapeutics stock hits 52-week low at $8.49 - Investing.com India
Iteos Therapeutics stock hits 52-week low at $8.49 By Investing.com - Investing.com South Africa
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress - GlobeNewswire
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Purchased by nVerses Capital LLC - Defense World
Iteos Therapeutics stock hits 52-week low at $8.73 - Investing.com India
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):